

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A pharmaceutical composition, comprising an antisense oligonucleotide which inhibits expression of TRPM-2 by tumor cells, and a pharmaceutically acceptable carrier suitable for human administration for providing the oligonucleotide to a mammalian subject to reduce expression of TRPM-2 wherein the antisense oligonucleotide comprises ~~has~~ the sequence given by SEQ ID No. 4.
- 2 - 11. (canceled)
12. (previously presented) The composition of claim 1, further comprising a second antisense oligodeoxynucleotide which inhibits expression of an anti-apoptotic protein other than TRPM-2.
13. (original) The composition of claim 12, wherein the second antisense oligodeoxynucleotide is antisense Bcl-2 oligodeoxynucleotide.
14. (canceled)
15. (previously presented) The composition of claim 13, wherein the antisense oligonucleotide having the sequence given by SEQ ID No. 4 is modified to increase the stability of the ODN *in vivo*.
- 16-18. (canceled)
19. (original) An oligonucleotide consisting of the sequence set forth in Seq. ID No. 4.
- 20-22. (canceled)
23. (previously presented) The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is a lipid carrier.
24. (previously presented) The pharmaceutical composition according to claim 1, further comprising an additional antisense oligonucleotide that binds specifically to a sequence other than TRPM-2 mRNA.

Appln No.: 09/944,326

Amendment Dated: May 29, 2006

Reply to Office Action of April 4, 2006

25. (original) The pharmaceutical composition according to claim 24, wherein the additional antisense oligonucleotide binds specifically to a sequence selected from among Bcl-2, Bcl-1x and c-myc.
26. (original) The pharmaceutical composition according to claim 25, wherein the additional oligonucleotide consists of the sequence set forth in the Seq. ID No. 13.
27. (canceled)
28. (new) The pharmaceutical composition of claim 1, wherein the oligonucleotide has a length of 18 to 21 bases.
29. (new) The pharmaceutical composition of claim 1, wherein the oligonucleotide has a length of 21 bases.
30. (new) The pharmaceutical composition of claim 1, where the oligonucleotide consists of the sequence given by SEQ ID No. 4.